Skip to content

Metabolic Phenotyping in Anorexia Nervosa

Metabolic Phenotyping to Predict Risk of Relapse in Patients With Anorexia Nervosa

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02087280
Enrollment
0
Registered
2014-03-14
Start date
2014-10-31
Completion date
2016-08-31
Last updated
2017-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Brief summary

After discharge from inpatient treatment, 30-50% of patients with Anorexia Nervosa require re-hospitalization within 4-12 months. So far, high relapse rates are mostly considered as lack of the patient's compliance and motivation to recover. However in studies, psychological relapse predictors explain only a minor part of the variance in relapse risk. Metabolic phenotyping has clinical value to predict weight course in obese patients and we assume that it could also be clinically relevant in patients with AN. We hypothesize that in patients with a dissipative but not with the thrifty phenotype, positive energy balance during refeeding causes an over proportional rise in energy expenditure, counteracts continuous weight gain during inpatient treatment, and increases relapse risk within one year after discharge. Thus we believe that metabolic phenotype as a biological parameter has prognostic value for the disease course in AN.

Interventions

None listed

Sponsors

Deutsche Forschungegemeinschaft
CollaboratorUNKNOWN
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Diagnosis of Anorexia Nervosa * Between 12 and 18 years of age * Written and informed consent of patient and parents * Mental ability to understand the concept of the study * Inpatient admission to Charité University Clinic with body weight below the 10th BMI-Percentile

Exclusion criteria

* Any further disease other than AN with significant influence on body composition and energy metabolism or its assessment

Design outcomes

Primary

MeasureTime frame
Relapse1 year after discharge

Secondary

MeasureTime frame
Metabolic phenotypeBaseline (during inpatient stay)
BiomarkersBaseline (during inpatient stay)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026